Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved ProteqFlu opvejer risiciene til aktiv immunisering af heste, der er 4 måneder gamle eller derover, mod hesteinfluenza for at nedsætte de kliniske symptomer og virusudskillelsen efter infektion samt mod stivkrampe for at forebygge dødelighed.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProteqFlu exceed the risks for the active immunisation of horses of 4 months of age or older against equine influenza to reduce clinical signs and virus excretion after infection, and against tetanus to prevent mortality.